A CRISPR-based SARS-CoV-2 diagnostic assay that is robust against viral evolution and RNA editing

Kean Hean Ooi[1,2,4], Jie Wen Douglas Tay[1,2,3,4], Seok Yee Teo[1,2,3,4], Mengying Mandy Liu[1,2], Pornchai Kaewsapsak[2], Shengyang Jin[3], Yong-Gui Gao[3], Meng How Tan[1,2]

[1]School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 637459, Singapore

[2]Genome Institute of Singapore, Agency for Science Technology and Research, Singapore 138672, Singapore

[3]School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore

[4]These authors contributed equally.

[*]Correspondence: mh.tan@ntu.edu.sg or tanmh@gis.a-star.edu.sg

Abstract (150 words)

Extensive testing is essential to break the transmission of the new coronavirus SARS-CoV-2, which causes the ongoing COVID-19 pandemic. Recently, CRISPR-based diagnostics have emerged as attractive alternatives to quantitative real-time PCR due to their faster turnaround time and their potential to be used in point-of-care testing scenarios. However, existing CRISPR-based assays for COVID-19 have not considered viral genome mutations and RNA editing in human cells. Here, we present the VaNGuard (Variant Nucleotide Guard) test that is not only specific and sensitive for SARS-CoV-2, but can also detect the virus when its genome or transcriptome has evolved or has been edited by deaminases in infected human cells. We show that an engineered AsCas12a enzyme is more tolerant of mismatches than wildtype LbCas12a and that multiplexed Cas12a targeting can overcome the presence of single nucleotide variations. Our assay can be completed in 30 minutes with a dipstick for a rapid point-of-care test.

Keywords: CRISPR; Diagnostics; COVID-19

Introduction

COVID-19 is an ongoing global pandemic caused by SARS-CoV-2, a novel coronavirus of zoonotic origin. The outbreak was first reported in Wuhan, China[1-3] and has since spread to more than 200 countries in all continents. As of 26 May 2020, there are over 5.4 million confirmed cases and 340,000 deaths worldwide, underscoring the severity of the disease. Importantly, given the high human-to-human transmission potential of SARS-CoV-2 including from asymptomatic carriers[4-6], rapid and accurate diagnosis is critical for timely treatment and outbreak control. Currently, quantitative real-time PCR (qRT-PCR) is the gold standard method to detect COVID-19. However, it requires specialized and expensive instrumentation to run and thus must be carried out in dedicated facilities with the necessary equipment and expertise. Furthermore, the turnaround time for qRT-PCR is too slow. Even excluding the time it takes to transfer samples from collection points to the test facilities, the PCR process itself will take more than an hour to run. Besides qRT-PCR, serological tests that detect antibodies against SARS-CoV-2 are actively under development. However, such tests have limited practical use for identifying infectious individuals as antibodies are only detectable in later stages of infection when opportunities to treat and limit disease transmission have passed. Hence, there is still an unmet need for rapid, specific, and sensitive point-of-care tests (POCT) for SARS-CoV-2 that are easy to use and can be performed in resource-limited settings.

CRISPR-Cas has emerged as a powerful technology that can potentially drive next-generation diagnostic platforms. After binding to and cutting a specific target substrate, certain Cas enzymes are then hyperactivated to cleave all neighbouring nucleic acids indiscriminately[7-9]. By programming the Cas nuclease to recognize desired sequences, such as those containing cancer mutations or from pathogens-of-interest, and providing single-stranded DNA (ssDNA) or RNA reporter molecules in the reaction mix, various groups have successfully developed CRISPR-based diagnostics (CRISPR-Dx) for a range of applications[9-14]. Unsurprisingly, it has also not escaped attention that the same technology can be quickly applied to tackle the ongoing COVID-19 outbreak. Within a few months, nine different CRISPR-based assays have been announced so far (Table 1)[15-23], underscoring the ease-of-use and versatility of the technology.

68   While promising, all the existing CRISPR-Dx for COVID-19 have not considered the

69   possibility that the viral sequences may be altered over time or in human cells. Viruses are

70   known to mutate especially under selective pressure. Thousands of SARS-CoV-2 genomes

71   had been sequenced and deposited in the GISAID database[24,25] and analysis of their

72   sequences revealed numerous mutations, suggesting an ongoing adaptation of the coronavirus

73   to its novel human host[26]. In particular, mutations had been discovered in the target sites of

74   many current COVID-19 diagnostic tests and could affect the performance of these qRT-PCR

75   tests[27]. Moreover, mutations in the SARS-CoV-2 genome may also create mismatches in the

76   guide RNA (gRNA) binding site and consequently affect the Cas ribonucleoprotein (RNP)

77   complex's ability to recognize its target. In addition, ADAR and APOBEC deaminases form

78   part of the human host's innate immune responses to viral infection and had recently been

79   shown to edit SARS-CoV-2 RNA[28]. The respective adenosine-to-inosine and cytosine-to-

80   uracil changes may also affect the ability of the CRISPR-Cas system to detect the virus.

81

82   Here, we report the development of CRISPR-Dx for COVID-19 that incorporate design

83   features that mitigate the loss in signal caused by genomic mutations or RNA editing. We

84   screened several different Cas12a enzymes and found that enAsCas12a, an engineered variant

85   of AsCas12a[29], was able to tolerate mismatches at the target site better than wildtype Cas12a

86   nucleases. Furthermore, we demonstrated that incorporation of two gRNAs into the CRISPR-

87   Cas system resulted in partial rescue of the output signal when a variant nucleotide was

88   present in the substrate. Notably, while our assay could tolerate single nucleotide variations

89   in the target sites, it still maintained high specificity and was able to distinguish SARS-CoV-

90   2 from SARS-CoV and MERS-CoV reliably. Taken together, our VaNGuard (Variant

91   Nucleotide Guard) test holds the potential to address the need for a robust and rapid

92   diagnostic assay that will help arrest viral spread and enable worldwide economies to re-open

93   safely in the pandemic.

94

95

96

97

98

99

100

101

4

102

103 **Results**

104

105 **Characterization of an existing N-gene gRNA**

106

107 We started off by examining the design of the earliest CRISPR-based assay for COVID-19[15].

108 In this DETECTR assay, wildtype LbCas12a was paired with a 20-nucleotide (nt) gRNA

109 targeting the N-gene of SARS-CoV-2. Given that various Cas12 enzymes had been

110 successfully utilized for human genome engineering, we asked if LbCas12a was the best

111 nuclease to deploy in a diagnostic test. To this end, we purified five different Cas12a

112 enzymes and then paired each one of them with the same gRNA (herein termed N-Mam

113 gRNA) in a fluorescence trans-cleavage assay (Fig. 1a). To assess the feasibility of a

114 CRISPR-based diagnostic assay being deployed in a non-laboratory setting (e.g. a home

115 setting), we carried out the reactions at room temperature using a 500-base pair (bp) synthetic

116 DNA fragment of the SARS-CoV-2 N gene. Fluorescence was monitored over the course of

117 30 minutes in a microplate reader (Supplementary Fig. 1). Expectedly, LbCas12a was able to

118 clearly detect SARS-CoV-2 with no cross-reactivity for SARS-CoV or MERS-CoV at the

119 end of the reaction. Nevertheless, the other four Cas12a enzymes also performed similarly to

120 LbCas12a, with enAsCas12a yielding an even higher fluorescence signal than LbCas12a in

121 the presence of the intended SARS-CoV-2 substrate (Fig. 1b). We also found that the

122 minimum spacer length for the N-Mam gRNA was 20nt, as shortening of the spacer led to a

123 reduction in fluorescence output for all the tested nucleases.

124

125 Next, we tested how mismatches at the gRNA-substrate interface may affect the fluorescence

126 signal. We generated ten new gRNAs targeting the same N-Mam locus, with each harbouring

127 a single point mutation at variable locations along the spacer (Fig. 1c). From the trans-

128 cleavage assay, we observed that LbCas12a was very sensitive to imperfect base pairing

129 between the gRNA and the substrate, as any mismatch along the spacer reduced the

130 fluorescence output to near-background levels (Fig. 1d and Supplementary Fig. 2). In contrast,

131 AsCas12a and its variants were able to tolerate a mismatch 4nt from the 3' end of the gRNA

132 (MM9). Furthermore, we found that enAsCas12a was the most tolerant to mismatches among

133 the five tested enzymes. Hence, our results suggest that enAsCas12a should be paired with

134 the N-Mam gRNA to safeguard against viral mutations or RNA editing at the target site.

135

Evaluation of RT-LAMP parameters

To enhance sensitivity, CRISPR-Cas detection is typically combined with an isothermal amplification step, of which there are several options. Due to supply chain issues in the ongoing pandemic, reverse transcription loop-mediated isothermal amplification (RT-LAMP)[30] is the method-of-choice for COVID-19 applications. In the DETECTR assay, the RT–LAMP reaction was performed at 62°C for 20–30 minutes[15]. Therefore, we first carried out RT-LAMP at 62°C for 20 minutes on synthetic *in vitro*-transcribed (IVT) SARS-CoV-2 RNA templates and then used the amplified products in our fluorescence trans-cleavage assay (Fig. 2 and Supplementary Fig. 3). For all the tested enzymes, the viral sequence was consistently and clearly detected in every replicate when 20,000 or more copies of RNA were used as input to RT-LAMP. However, in contrast to the published report[15], when 2,000 copies of RNA were used in a 25µl RT-LAMP reaction (i.e. 80 copies per µl) instead, the viral sequence was detected in only around half the replicates for all the Cas enzymes, including LbCas12a.

Subsequently, we asked how the sensitivity of the CRISPR-based assay would be affected if we varied the parameters of the LAMP reaction (Fig. 2 and Supplementary Fig. 3). When we decreased the duration of LAMP from 20 to 12 minutes, we observed that the fluorescence signal showed an exponential decay with every 10-fold reduction in RNA copy number, indicating that the analytic limit of detection (LoD) became poorer if the amplification step was performed for too short a period of time. Interestingly however, when we increased the reaction temperature from 62°C to 65°C while keeping the duration at 12 minutes, we were able to partially recover the fluorescence signal. Further increase in temperature from 65°C to 68°C caused a deterioration in the performance of our CRISPR-Dx (Supplementary Fig. 4). Hence, our results suggest that 65°C is the optimal temperature for LAMP and that the amplification reaction is sensitive to small variations in temperature.

Screening of additional gRNAs

We wondered if there may be other gRNAs that could yield a stronger fluorescence signal than the N-Mam gRNA in our trans-cleavage assay. The genome of SARS-CoV-2 contains two open reading frames (ORFs), ORF1a and ORF1b, that encode multiple non-structural proteins (nsps), four genes that encode conserved structural proteins (spike protein [S],

7

170   envelope protein [E], membrane protein [M], and nucleocapsid protein [N]), and several

171   accessory ORFs of unclear function (Fig. 3a)[31]. We aligned the genomes of SARS-CoV-2,

172   SARS-CoV, and MERS-CoV and selected six additional target sites (O1, O2, S1, S2, S3, and

173   N1) that not only contained the necessary TTTV protospacer adjacent motif (PAM) for

174   Cas12a but were also highly divergent between the three coronaviruses (Supplementary Fig.

175   5). We then analysed the collateral activities of our five Cas12a enzymes paired with each of

176   the six new gRNAs over the course of 30 minutes using synthetic DNA fragments of the

177   relevant genes as targets. Curiously, when the N1 gRNA was paired with either wildtype

178   AsCas12a or any of its engineered variants (enAsCas12a, enRR, and enRVR)[29], we were able

179   to detect some fluorescence signal even in the absence of template (Fig. 3b and

180   Supplementary Fig. 6), suggesting that AsCas12a may be hyper-activated by certain gRNAs

181   *in vitro* without the need for it to cleave its intended target. Such a phenomenon was not

182   observed with LbCas12a.

183

184   Overall, the three S-gene gRNAs were able to generate similar or higher fluorescence signals

185   than the N-Mam gRNA with the appropriate Cas12a nuclease, while the two O-gene gRNAs

186   generally performed worse. In particular, in the presence of the SARS-CoV-2 target, the

187   collateral activity of LbCas12a complexed with the S3 gRNA was approximately double that

188   of the same enzyme complexed with the N-Mam gRNA (Fig. 3b and Supplementary Fig. 6).

189   There was no cross-reactivity for SARS-CoV or MERS-CoV. We also confirmed that the

190   activity of our own purified protein was comparable to that of a commercially available

191   LbCas12a enzyme used in several recently announced CRISPR-based COVID-19 diagnostic

192   assays[15,20,21] (Fig. 3c). Subsequently, we investigated the mismatch tolerance of LbCas12a at

193   the S3 target locus but found that collateral activity was greatly diminished for all the

194   mismatched (MM) gRNAs tested (Fig. 3d, e and Supplementary Fig. 7). Hence, although the

195   S3 gRNA may be used in a highly specific assay for known SARS-CoV-2 isolates, it is not

196   ideal for a diagnostic assay that is robust against potential mutations at the target site.

197

198   **Detailed characterization of a new S-gene gRNA**

199

200   Next, we turned our attention to the S2 gRNA. In the presence of the SARS-CoV-2 substrate,

201   this gRNA generated stronger fluorescence signals than the N-Mam gRNA when paired with

202   LbCas12a, AsCas12a, enAsCas12a, or enRVR (Fig. 4a and Supplementary Fig 8). The

203   engineered enAsCas12a enzyme exhibited the highest collateral activity with the S2 gRNA.

8

204 Importantly, no cross-reactivity for SARS-CoV or MERS-CoV was observed regardless of
205 the Cas12a nuclease used. Furthermore, we found that the minimum spacer length for the S2
206 gRNA was 20nt, as shortening of the spacer reduced the collateral activity of all tested
207 nucleases, although unexpectedly, the 18nt gRNA gave higher fluorescence signals than the
208 19nt gRNA.

209

210 We sought to determine how mismatches at the S2 gRNA-substrate interface may affect the
211 collateral activity of the Cas12a enzymes. To this end, we generated ten additional gRNAs
212 with each harbouring a point mutation at different positions along the spacer (Fig. 4b).
213 Interestingly, we found from the trans-cleavage assay that individual mismatches at the S2
214 locus affected the collateral activity of all the Cas12a endonucleases much less than those at
215 the N-Mam locus (Fig. 4c and Supplementary Fig. 9). Nevertheless, enAsCas12a and enRVR
216 again exhibited the highest tolerance for mismatches, while wildtype LbCas12a was again the
217 most sensitive to imperfect base pairing between the gRNA and its target substrate.

218

219 So far, we had performed the CRISPR-Cas detection at room temperature (24^oC) to simulate
220 a non-laboratory setting, but we wondered how the performance of our diagnostic assay
221 would improve if the detection was performed at the optimal temperature (37^oC) of the
222 Cas12a enzymes instead. From the trans-cleavage assay, we observed that the fluorescence
223 signal increased approximately twice as fast at 37^oC for all tested enzymes in the presence of
224 the intended SARS-CoV-2 template and reached significantly higher levels after 30 minutes
225 of reaction ($P < 0.01$, Student's t-test) (Fig. 4d and Supplementary Fig. 10). There was again
226 no cross-reactivity for SARS-CoV and MERS-CoV. In addition, the activity profile in the
227 presence of point mutations remained similar and in fact even improved slightly for all the
228 nucleases with respect to mismatch tolerance (Fig. 4e and Supplementary Fig. 10). Taken
229 together, our results indicate that our CRISPR-based assay should be performed at 37^oC if a
230 faster test result is desired and also suggest that the S2 gRNA is more suitable than the N-
231 Mam gRNA in a diagnostic assay that guards against viral evolution or intracellular RNA
232 editing.

233

234 **Multiplex Cas12a targeting**

235

236 Besides searching for Cas-gRNA pairs that are not only specific for SARS-CoV-2 but are
237 also tolerant of mismatches at the binding site, another strategy to enhance robustness is to

238 incorporate two or more distinct gRNAs into the detection module. As a proof-of-concept, we

239 sought to buffer the collateral activity of LbCas12a, which appeared to be more sensitive to

240 imperfect base pairing at the gRNA-target interface than AsCas12a and its engineered

241 variants. Moreover, LbCas12a protein is commercially available and can be readily bought by

242 diagnostic laboratories that do not have the ability to purify their own enzymes. To keep all

243 the target sites within the same LAMP products, we may pair the S2 gRNA with either the S1

244 or the S3 gRNA, as both worked well with LbCas12a (Fig. 3b and Supplementary Fig. 6). We

245 then tried to design LAMP primers using the online software PrimerExplorer V5. However,

246 we were unable to find any set of primers that would produce an amplicon smaller than

247 500bp that contained both the S2 and S3 loci. In contrast, many primer sets could be obtained

248 for S1 and S2. Hence, we decided to perform our multiplexed targeting experiments with the

249 S1 and S2 gRNAs.

250

251 Using a synthetic DNA fragment of the SARS-CoV-2 S gene as substrate, we first assessed

252 the collateral activity of our five purified Cas12a enzymes when they were combined with

253 both the S1 and S2 gRNAs. All five nucleases exhibited robust activity with perfect matched

254 (PM) gRNAs (Fig. 4f and Supplementary Fig. 11). However, we noted that addition of the S1

255 gRNA caused a small but obvious reduction in the trans-cleavage activity of the three

256 AsCas12a variants, while that of LbCas12a remained approximately the same. This was

257 likely because the S1 gRNA would compete with the S2 gRNA for the Cas proteins but only

258 LbCas12a exhibited strong activity with the S1 gRNA (Fig. 3b and Supplementary Fig. 6).

259 Subsequently, we profiled the activity of the Cas12a nucleases when the S1 PM gRNA was

260 used together with each one of the S2 MM gRNAs (Fig. 4g and Supplementary Fig. 11).

261 Strikingly, we now observed that LbCas12a exhibited the best overall tolerance for

262 mismatches, while AsCas12a and its engineered variants became more sensitive to the

263 mismatches.

264

265 Next, we sought to determine the analytic limit of detection (LoD) of our CRISPR-Dx. We

266 tested three sets of LAMP primers and found one set that amplified well even with low

267 amounts of template (Supplementary Fig. 12). Therefore, we carried out RT-LAMP on

268 synthetic *in vitro*-transcribed (IVT) SARS-CoV-2 RNA templates using this selected primer

269 set. The reaction was performed at 65°C for 15 minutes because we had earlier found the

270 temperature to be optimal for LAMP and we sought to minimize the duration of our

271 diagnostic test. The amplified products were used immediately in our trans-cleavage assay,

10

272   with the fluorescence monitored over time in a microplate reader (Fig. 5 and Supplementary

273   Fig. 13). When only a single S2 PM gRNA was used, we found that the LoD was around 200

274   copies per reaction for all tested Cas12a nucleases. Expectedly, introduction of a single

275   mismatch (MM10) at the gRNA-substrate interface worsened the sensitivity of CRISPR-Cas

276   detection. More importantly, addition of a S1 PM gRNA was able to partially rescue the

277   mismatch at the S2 locus for LbCas12a, but not for the other Cas12a enzymes. Taken

278   together, our trans-cleavage assays revealed that the use of two gRNAs could increase the

279   robustness of CRISPR-Dx with respect to the presence of variant nucleotides, but care must

280   be taken to only utilize gRNAs that would work well together with the selected Cas nuclease.

281

282   **Towards a point-of-care test**

283

284   To broaden the use cases of our diagnostic assay, we sought to develop a portable point-of-

285   care test (POCT). After the CRISPR-Cas trans-cleavage reaction has taken place, the results

286   can be read out in different ways (Fig. 6a). While a microplate reader is useful for high

287   throughput screening of samples in a centralized facility, it is not amenable to non-laboratory

288   settings like ports of entry, workplaces, schools, public spaces, and homes. Hence, we

289   decided to visualize the results of our assay on a lateral flow strip (Supplementary Fig. 14).

290   Here, the reporter molecule consists of a fluorescent dye (fluorescein) linked to biotin by a

291   short piece of ssDNA. An anti-fluorescein antibody conjugated to gold binds to the dye on

292   the strip. When the viral substrate is absent, the reporter is intact and captured by streptavidin

293   at the control line. However, when the viral target is present, the reporter is cleaved and the

294   fluorescein-antibody complex migrates to the test line where it is captured by an immobilized

295   secondary antibody.

296

297   We performed the RT-LAMP reaction at 65°C for 15 minutes followed by the CRISPR-Cas

298   trans-cleavage reaction at 37°C for 10 minutes before adding a lateral flow strip to the

299   reaction tube. Bands appeared at either the test line or the control line within two minutes

300   (Fig. 6b). Hence, in total, the entire assay took slightly under 30 minutes to complete. Here,

301   we focused on LbCas12a to demonstrate the utility of multiplex targeting. The S2 gRNA (PM

302   or MM10) was used in the assay with or without a second S1 PM gRNA. We also tested

303   different copy numbers of the synthetic SARS-CoV-2 RNA template. Overall, we found that

304   our lateral flow assays gave results that mirrored those from a microplate reader. When the

305   S2 PM gRNA was used alone or in conjunction with the S1 PM gRNA, dark bands appeared

11

306   at the test line in the presence of at least 200 copies of template in the reaction mix.
307   Expectedly, without any multiplexing, introduction of a mismatch at the S2 gRNA-target
308   interface dramatically reduced the intensity of the test bands and worsened the analytic LoD
309   to 2,000 copies per reaction. Importantly, addition of the S1 PM gRNA was able to partially
310   restore the intensity of the test bands. Quantification of the test and control band intensities
311   further provided a more objective measure of whether the intended target was detected or not.
312   In the case of a mismatch at the S2 locus but perfect base pairing at the S1 locus, we were
313   able to tell that 200 copies per reaction gave a positive test result based on the ratio of the test
314   to control band intensities. In the future, a web or mobile phone application can be developed
315   to distinguish such borderline cases.

316

Discussion

318

319   There is an urgent healthcare need for rapid and accurate diagnostic tests for COVID-19.
320   What initially started as an infectious disease confined to Wuhan, China has since spread to
321   more than 200 countries worldwide within the span of a few months because SARS-CoV-2
322   has a high potential for human-to-human transmission and the majority of carriers are
323   asymptomatic or only mildly ill. At present, qRT-PCR serves as the gold standard for viral
324   detection, with dozens of test kits available in the market. However, the method requires
325   dedicated instrumentation and trained operators and also has a slow turnaround time. Hence,
326   there is still an unmet need for a rapid, sensitive, specific, and affordable SARS-CoV-2
327   diagnostic assay, which is essential for stopping viral spread and for the safe reopening of
328   economies and schools.

329

330   CRISPR-Dx has the potential to meet society's need for such a diagnostic test. The entire
331   workflow consists of four main modules (Fig. 6a). First is the sample input. Although
332   purified RNA is ideal for performance, the process of RNA extraction will take up precious
333   time, increase cost, and stress the supply chain. Therefore, there is great interest in
334   developing assays that can directly handle patient samples, including nasopharyngeal swabs
335   and saliva. The second module is the isothermal amplification step, which is commonly
336   implemented to enhance the sensitivity of CRISPR-Dx. LAMP[30] is the method-of-choice in
337   the current pandemic climate, as its reagents are readily available from several suppliers, but
338   other approaches can also be used, including recombinase polymerase amplification (RPA)[32]

12

339   and helicase-dependent amplification (HDA)[33]. The third module is the CRISPR-Cas

340   detection system. Most CRISPR-Dx rely on an indiscriminate collateral activity possessed by

341   some Cas nucleases, including Cas12, Cas13, and Cas14 family members. Lastly, the fourth

342   module is the assay readout. While our work here has demonstrated the use of a microplate

343   reader (for high-throughput testing) and a lateral flow strip (for POCT), another possibility is

344   a graphene-based field-effect transistor, whose high sensitivity has been reported to obviate

345   the need for a pre-amplification step[34]. Overall, the cost of running a CRISPR-based test per

346   sample is under S$9 (Table 2), which is around US$6.40 or €5.80 and is similar to that of an

347   off-the-shelf pregnancy test. The bulk of the cost comes from the LAMP mastermix and the

348   dipstick.

349

350   While promising, current CRISPR-Dx assays for COVID-19 (Table 1) have not taken into

351   account viral evolution and RNA editing. Alarmingly, mutations in the SARS-CoV-2 genome

352   have been observed at the target sites of multiple existing qRT-PCR diagnostic tests[27].

353   Moreover, RNA editing mediated by the ADAR and APOBEC enzymes can also impact

354   upon the performance of COVID-19 diagnostics. Hence, in this work, we sought to bolster

355   the robustness of CRISPR-Dx against unexpected variant nucleotides introduced by

356   evolutionary pressures or RNA editing. Starting from the DETECTR platform[9,15], we tested

357   several different natural and engineered Cas12a enzymes and found that enAsCas12a

358   exhibited the highest tolerance for single mismatches at the gRNA-target interface.

359   Importantly, high specificity for SARS-CoV-2 was still maintained with enAsCas12a, as no

360   cross-reactivity for two other closely related coronaviruses SARS-CoV and MERS-CoV was

361   observed. We also screened additional gRNAs and discovered that all the tested nucleases,

362   except enRR, exhibited higher trans-cleavage activity with the S2 gRNA than with the N-

363   Mam gRNA. Hence, our results indicate that enCas12a complexed with the S2 gRNA will

364   serve as a more sensitive and robust SARS-CoV-2 detection system than the published

365   LbCas12a and N-Mam gRNA pair. Nevertheless, we are mindful that enCas12a is not yet a

366   commercially available enzyme. Hence, we demonstrated that a multiplex targeting strategy

367   could also be utilized to enhance the robustness of CRISPR-Dx. For example, the LbCas12a

368   nuclease, which is readily bought, may be combined with both the S1 and S2 gRNAs to

369   increase the robustness of viral detection.

370

371   We note that diagnostic assays can be constructed out of isothermal amplification methods

372   alone without coupling them to a separate CRISPR-Cas detection module. Such assays

373   typically rely on the use of a turbidimeter to measure the extent of magnesium precipitation,

374   labelled primers, or special dyes that sense pH changes, react with amplification by-products,

375   or bind to double-stranded DNA (dsDNA). Due to their relative simplicity, over a dozen

376   LAMP-only diagnostic assays for COVID-19 have been developed so far[35-49]. However,

377   isothermal amplification frequently produces spurious non-specific products, which can give

378   rise to false positive results. Although this problem may be circumvented by the use of a

379   sequence-specific detection probe that is distinct from the LAMP primers[43], the probe itself is

380   not involved in any amplification process. In contrast, CRISPR-Dx confers two distinct

381   rounds of specificity. The first round comes from primer-specific isothermal amplification

382   such as LAMP, while the second round comes from gRNA-specific Cas detection.

383   Furthermore, the CRISPR-Cas detection system is also capable of signal amplification

384   because each hyperactivated Cas nuclease can proceed to cleave numerous reporter

385   molecules. Hence, CRISPR-Dx can function like a photomultiplier tube and the assay

386   duration can potentially be shortened if all the reagents are in a single-pot and the conditions

387   are optimal for every reaction.

388

389   In conclusion, CRISPR-Dx can serve as a rapid, specific, sensitive, and affordable approach

390   for the detection of SARS-CoV-2. Our work here has further provided two different strategies,

391   namely the use of enCas12a and multiplex targeting, to enhance the robustness of the assay.

392   It can be implemented in a high-throughput format through the use of a microplate reader or

393   deployed as a POCT through the use of a lateral flow strip to enable us to halt viral

394   transmission and reopen our society safely.

395

396

397

14

Methods

Plasmids and oligonucleotides

The pET28b-T7-Cas12a-NLS-6xHis expression plasmids were gifts from Keith Joung and Benjamin Kleinstiver (Addgene plasmid #114069 [AsCas12a], #114070 [LbCas12a], #114072 [enAsCas12a], #114075 [enRVR], and #114077 [enRR])[29]. DNA oligonucleotides, custom reporters for the trans-cleavage assays, and gene fragments (ORF1AB, S, and N) for the three coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV were synthesised by Integrated DNA Technologies. All oligonucleotides used in this study are listed in Supplementary File 1.

Cas12a expression and purification

The Cas12a expression plasmids were transformed into *Escherichia coli* BL21 (DE3) and stored as glycerol stocks. Starter cultures were grown in LB broth with 50µg/ml kanamycin at 37°C for 16h and diluted 1:50 into 400ml LB-kanamycin broth until an OD_{600} of 0.4-0.6 was reached. Cultures were then induced with 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated at 25°C for another 16h. Subsequently, cells were harvested by centrifugation at 3,220g for 20min and resuspended in lysis buffer [50mM HEPES, 500mM NaCl, 2mM $MgCl_2$, 20mM imidazole, 1% Triton X-100, 1mM DTT, 0.005mg/ml lysozyme (Vivantis), 1X Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific)], followed by sonication at high power for 10 cycles of 30s ON/OFF (Bioruptor Plus; Diagenode). Lysates were clarified by centrifugation at 10,000g for 15min. The supernatants were pooled, loaded onto a gravity flow column packed with Ni-NTA agarose (Qiagen), and rotated for 2h at 4°C. The column was washed twice with 5ml wash buffer (50mM Tris, 300mM NaCl and 30mM imidazole). Five elutions were performed with 500µl elution buffer (50mM Tris, 300mM NaCl, and 200mM imidazole) and analysed by SDS-PAGE. The final gel filtration step was performed with a HiLoad 16/600 Superdex 200pg column (GE Healthcare) on a fast protein liquid chromatography purification system (ÄKTA Explorer; GE Healthcare), which was eluted with storage buffer (50mM Tris, 300mM NaCl, and 1mM DTT). Fractions containing Cas12a were collected, analysed by SDS-PAGE, and concentrated to around 500µl with Vivaspin 20, 50,000 MWCO concentrator units (Sartorius). Glycerol was added to a final concentration of 20%. Protein concentrations were measured with the Quick Start Bradford

15

430   Protein Assay (Bio-Rad) aliquoted, and stored at -80°C. For comparison, EnGen Lba Cas12a

431   was purchased from New England Biolabs (NEB).

432

433   **gRNA design**

434   Complete genomes of SARS-CoV-2 (accession MN908947.3), SARS-CoV (accession

435   NC_004718.3), and MERS-CoV (accession NC_019843.3) were retrieved from NCBI

436   (https://www.ncbi.nlm.nih.gov/) and aligned with MUSCLE

437   (https://www.ebi.ac.uk/Tools/msa/muscle/) using default settings. Potential target sites (20nt

438   spacers) in the ORF1AB, S, and N genes were selected from non-conserved regions

439   containing a TTTV PAM. Potential targets were filtered after a specificity check on BLASTn

440   (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to remove non-specific candidates. Truncated

441   gRNAs were generated by shortening their spacers to 18nt and 19nt lengths at the 3' end.

442

443   *In vitro* **transcription (IVT) of gRNAs**

444   Templates for gRNA synthesis were designed with the following sequence order: T7

445   promoter-Cas12a scaffold-spacer. Top strand DNA oligos consisting of the T7 promoter (5'-

446   TAATACGACTCACTATAGG-3') and scaffold (5'-TAATTTCTACTCTTGTAGAT-3' for

447   AsCas12a and its variants; 5'-AATTTCTACTAAGTGTAGAT-3' for LbCas12a) were

448   annealed to the bottom strand and extended by Q5 High-Fidelity DNA polymerase (NEB).

449   IVT of the dsDNA products was performed with the HiScribe T7 Quick High Yield RNA

450   Synthesis kit (NEB) at 37°C overnight. Following DNase I digestion, gRNAs were purified

451   with the RNA Clean & Concentrator-5 kit (ZYMO Research), analysed by 2% TAE-agarose

452   gel electrophoresis to assess RNA integrity, measured with NanoDrop 2000, and stored at -

453   20°C.

454

455   **Synthesis of DNA and RNA templates**

456   Gene fragments (gBlocks) were cloned into pCR-Blunt II-TOPO vector using the Zero Blunt

457   TOPO PCR Cloning kit (Invitrogen) and their sequences were verified by Sanger sequencing.

458   The vectors were used as templates for PCR with Q5 High-Fidelity DNA polymerase (NEB)

459   and the products were gel extracted and purified with the PureNA Biospin Gel Extraction kit

460   (Research Instruments). DNA concentrations were measured using NanoDrop 2000 and all

461   the DNA samples were stored at 4°C. To generate RNA templates for RT-LAMP assays, the

462   forward primers used for PCR were appended with the T7 promoter sequence. After PCR

16

463 amplification with the gBlock-TOPO vectors as template, IVT was performed as described

464 for gRNA generation.

465

466 Fluorescence trans-cleavage assay

467 Cas ribonucleoprotein (RNP) complexes were pre-assembled with 65nM AsCas12a/

468 LbCas12a, 195nM gRNA, and 200nM custom ssDNA fluorophore-quencher (FQ) reporter in

469 reaction buffer (1X NEBuffer 3.1 plus 0.4mM DTT) for 30 minutes at room temperature.

470 Subsequently, the cleavage reaction was initiated by adding 3nM DNA template

471 (approximately 1E11 copies) to a total volume of 50μl and then transferred to a 96-well

472 microplate (Costar). Fluorescence intensities were measured with either the Infinite M1000

473 Pro (Tecan) or the Spectramax M5 plate reader (Molecular Devices) for 30 minutes at room

474 temperature, with measurement intervals of 5 minutes (λ_{ex}: 485 nm; λ_{em}: 535 nm).

475

476 RT-LAMP reaction

477 Synthetic SARS-CoV-2 RNA templates were serially diluted and amplified by RT-LAMP

478 using the WarmStart LAMP Kit (NEB). LAMP primers were added to a final concentration

479 of 0.2μM for F3 and B3, 1.6μM for FIP and BIP, and 0.8μM for LF and LB. The optimal

480 temperature for RT-LAMP was found to be 65°C. Subsequently, 4μl RT-LAMP products

481 were used as templates for the trans-cleavage assay, instead of 3nM PCR-amplified DNA

482 template.

483

484 Lateral flow readout

485 500nM of custom ssDNA biotin reporter was used instead of the FQ reporter. The Cas12a

486 detection reaction was performed at 37°C for 10 minutes. Subsequently, 50μL HybriDetect

487 assay buffer (Milenia Biotec) was added to the reaction and a HybriDetect (Milenia Biotec)

488 dipstick was inserted directly into the solution in an upright position. The dipstick was

489 incubated in the reaction for 2 minutes at room temperature before inspection.

490

491

492

17

Acknowledgements

Authors' contributions

M.H.T conceived the project and provided overall supervision. K.H.O., J.W.D.T., S.Y.T., and M.H.T. designed the experiments. K.H.O., J.W.D.T., S.Y.T., M.M.L., and P.K. performed the experiments. S.J. and Y.-G.G. assisted with protein purification. K.H.O., J.W.D.T., S.Y.T., and M.H.T. analysed the data. M.H.T. wrote the manuscript with inputs from K.H.O., J.W.D.T., and S.Y.T. All authors approved the manuscript.

Additional information

Supplementary Information accompanies this paper

Competing interests: The authors declare that they have no competing interests.

516 **Tables**

517

518 **Table 1.** List of CRISPR-based assays for COVID-19 that have been announced (as of 26 May 2020).

Name	DETECTR	CARMEN	CASdetec	STOPCovid	CRISPR-nCoV	CRISPR-Detection	AIOD-CRISPR	FELUDA	CREST
Status	Published[15]	Published[16]	Published[17]	MedRxiv preprint[18]	MedRxiv preprint[19]	BioRxiv preprint[20]	BioRxiv preprint[21]	BioRxiv preprint[22]	BioRxiv preprint[23]
Enzyme	LbCas12a	LwCas13a	AapCas12b	AapCas12b	LwCas13a	LbCas12a	LbCas12a	FnCas9	LwCas13a
Based on collateral activity	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Validated on patient samples	Yes (N = 11)	No	No	Yes (N = 12)	Yes (N = 52)	No	No	Yes (N = 1)	No
Affiliated company	Mammoth (partnering with GSK)	-	-	Sherlock	-	CASPR	-	Tata Sons	-

519

520

521 **Table 2.** Estimated cost of CRISPR-Dx for each sample.

Reagent	Approximate Price (S$)	Number of Reactions	Price per reaction (S$)	
			Plate reader	Dipstick
RNA extraction kit	1,200	90,800	0.01	0.01
IVT Kit	491	22,700	0.02	0.02
RT-LAMP mastermix	1,489	500	2.98	2.98
Cleavage assay buffer	41	1,000	0.04	0.04
LbCas12a	450	600	0.75	0.75
LAMP primer (F3)	5	1,200	<0.01	<0.01
LAMP primer (B3)	5	1,200	<0.01	<0.01
LAMP primer (FIP)	10	125	0.08	0.08
LAMP primer (BIP)	10	125	0.08	0.08
LAMP primer (LF)	5	300	0.02	0.02
LAMP primer (LB)	5	300	0.02	0.02
FITC-quencher reporter	315	650	0.48	-
96-well plate	8	96	0.08	-
FITC-biotin reporter	200	5,555	-	0.04
Dipstick	490	100	-	4.90
		TOTAL	4.58	8.94

522

523

20

524 **Figure Legends**

525

526 **Fig. 1** Activity and mismatch tolerance of various Cas12a enzymes with the N-Mam gRNA.

527 **a** Schematic of a fluorescence trans-cleavage assay. Here, the reporter comprises a

528 fluorophore linked to a quencher by a short piece of ssDNA. The gRNA is programmed to

529 recognize a particular locus of the SARS-CoV-2 genome. In the absence of the virus, the

530 reporter molecule is intact and thus no fluorescence is observed. However, when the virus is

531 present, the Cas12a RNP will bind to and cleave its programmed target, become

532 hyperactivated, and cut the ssDNA linker between the fluorophore and quencher, thereby

533 generating a fluorescence signal.

534 **b** Fluorescence measurements using a microplate reader after 30 minutes of cleavage reaction.

535 1E11 copies of DNA template corresponding to one of the coronaviruses (see colour bar)

536 were present in a 50μl reaction. Spacers of three different lengths targeting the N-Mam locus

537 were tested. There was no cross-reactivity for SARS-CoV or MERS-CoV as expected. All

538 the measurements were normalized to the no-template control (NTC) at the start of the

539 experiment. Data represent mean ± s.e.m. (n = 3 biological replicates).

540 **c** Sequences of perfect matched (PM) or mismatched (MM) spacers targeting the N-Mam

541 locus. Each mismatched position is indicated by a bold red letter.

542 **d** Heatmap showing the tolerance of various Cas12a enzymes to mismatched N-Mam gRNAs.

543 The fluorescence readings are scaled between 0 and 1, where 1 is the highest measurement

544 obtained and 0 is the background signal for NTC at the start of the experiment.

545

546 **Fig. 2** Analytic limit of detection (LoD) under various LAMP reaction conditions. Different

547 copies of synthetic SARS-CoV-2 RNA fragments were used as input and the volume of each

548 RT-LAMP reaction was 25μl. The fluorescence readings here were taken after 10 minutes of

549 cleavage reaction. Data represent mean ± s.e.m. (62°C for 20min: n = 4-7 biological

550 replicates; 62°C/ 65°C for 12min: n = 3 biological replicates).

551

552 **Fig. 3** Collateral activity of various Cas12a enzymes complexed with different gRNAs.

553 **a** Organization of the SARS-CoV-2 genome. ORF1a and ORF1b occupy over half of the

554 genome. Genes encoding structural proteins are indicated by green boxes, while genes

555 encoding accessory proteins are indicated by cyan boxes. Although ORF10 is annotated in

556 the genome, there is currently no evidence of its expression[50]. The locations of the new

21

557   gRNAs are shown by pink bars below the genes, while the N-Mam locus is shown by a red

558   bar.

559   **b** Fluorescence measurements using a microplate reader after 30 minutes of cleavage reaction.

560   1E11 copies of the relevant DNA target were present in a 50μl reaction. All the readings were

561   normalized to the negative control (NTC) at the start of the experiment. The N1 gRNA gave

562   an unexpected result, whereby it triggered the collateral activity of AsCas12a and its variants

563   even in the absence of a template. Data represent mean ± s.e.m. (n = 3-6 biological replicates).

564   **c** Visualization of cleavage reactions for the S3 gRNA using a UV transilluminator.

565   Transition of colours from blue to yellow to red indicates an increasing amount of collateral

566   activity.

567   **d** Sequences of perfect matched (PM) or mismatched (MM) spacers targeting the S3 locus.

568   Each mismatched position is indicated by a bold red letter.

569   **e** Collateral activity of LbCas12a complexed with perfect matched or mismatched S3 gRNA.

570   The fluorescence measurements were taken after 30 minutes of cleavage reaction using a

571   microplate reader and all the readings were normalized to the NTC at the start of the

572   experiment. Our results indicate that LbCas12a should be paired with the S3 gRNA instead of

573   the N-Mam gRNA if a diagnostic assay that is highly specific for known SARS-CoV-2

574   isolates is desired. Data represent mean ± s.e.m. (n = 3 biological replicates).

575

576   **Fig. 4** Activity and mismatch tolerance of various Cas12a enzymes with the S2 gRNA.

577   **a** Fluorescence measurements for a single S2 gRNA after 30 minutes of trans-cleavage

578   reaction at 24^oC. 1E11 copies of DNA template corresponding to one of the three

579   coronaviruses (see colour bar) were present in a 50μl reaction. Spacers of three different

580   lengths targeting the S2 locus were tested. All the measurements were normalized to the

581   negative control (NTC) at the 0min timepoint. No cross-reactivity for SARS-CoV or MERS-

582   CoV was detected. Unexpectedly, the 18nt spacer yielded higher fluorescence than the 19nt

583   spacer for all the tested nucleases, especially LbCas12a. Data represent mean ± s.e.m. (n = 3-

584   4 biological replicates).

585   **b** Sequences of perfect matched (PM) or mismatched (MM) spacers targeting the S2 locus.

586   Each mismatched position is indicated by a bold red letter.

587   **c** Heatmap showing the tolerance of various Cas12a enzymes to mismatched S2 gRNAs

588   when the trans-cleavage assay was performed at 24^oC. The fluorescence readings are scaled

589   between 0 and 1 (variable shades of green), where 1 is the highest measurement obtained at

590   24^oC and 0 is the background signal for NTC at the start of the experiment.

591   **d** Fluorescence measurements for a single S2 gRNA after 30 minutes of trans-cleavage

592   reaction at 37°C. There was still no cross-reactivity for SARS-CoV or MERS-CoV at the

593   higher temperature, but the fluorescence signal for SARS-CoV-2 was approximately twice as

594   high. Data represent mean ± s.e.m. (n = 3 biological replicates).

595   **e** Heatmap showing the tolerance of various Cas12a enzymes to mismatched S2 gRNAs

596   when the trans-cleavage assay was performed at 37°C. The fluorescence readings are scaled

597   between 0 and 1 (variable shades of red), where 1 is the highest measurement obtained at

598   37°C and 0 is the background signal for NTC at the start of the experiment. The most

599   detrimental mismatch position appears to be 2nt from the PAM-distal end (MM10).

600   **f** Fluorescence measurements for two PM gRNAs (S1 and S2) after 30 minutes of cleavage

601   reaction at 37°C. No cross-reactivity for SARS-CoV or MERS-CoV was observed. Data

602   represent mean ± s.e.m. (n = 3 biological replicates).

603   **g** Heatmap showing how the addition of a second perfect matched S1 gRNA changed the

604   tolerance of various Cas12a enzymes to mismatched S2 gRNAs. The trans-cleavage assay

605   was performed at 37°C, with the fluorescence readings scaled between 0 and 1.

606

607   **Fig. 5** Analytic LoD for gRNAs targeting the S-gene. Different copies of *in vitro* transcribed

608   SARS-CoV-2 RNA fragments were used as input to the RT-LAMP reaction, which was

609   performed at 65°C for 15 minutes. The Cas detection reaction was then carried out at 37°C,

610   with the fluorescence measurements here taken after 10 minutes using a microplate reader.

611   Data represent mean ± s.e.m. (n = 3-5 biological replicates).

612

613   **Fig. 6** Implementation of our VaNGuard assay on lateral flow strips.

614   **a** Overview of a prototypical CRISPR-Dx workflow. While a microplate reader can allow up

615   to 96 samples to be processed at once, it is not amenable to point-of-care testing. In contrast,

616   a lateral flow strip proves a simple visual readout akin to an off-the-shelf pregnancy test.

617   **b** Detection of SARS-CoV-2 sequence using gRNAs targeting the S-gene. Different copies of

618   synthetic SARS-CoV-2 RNA fragments were used as input to the RT-LAMP reaction, which

619   was performed at 65°C for 15 minutes. Next, the Cas detection reaction was carried out at

620   37°C for 10 minutes before a dipstick was added to each reaction tube. The bands on the

621   dipstick appeared by 2 minutes. In total, the VaNGuard assay was completed in under 30

622   minutes.

23

References

1   Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).

2   Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).

3   Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. *Lancet* **395**, 470-473, doi:10.1016/S0140-6736(20)30185-9 (2020).

4   Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).

5   Bai, Y. *et al.* Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*, doi:10.1001/jama.2020.2565 (2020).

6   Rothe, C. *et al.* Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med* **382**, 970-971, doi:10.1056/NEJMc2001468 (2020).

7   Abudayyeh, O. O. *et al.* C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science* **353**, aaf5573, doi:10.1126/science.aaf5573 (2016).

8   East-Seletsky, A. *et al.* Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature* **538**, 270-273, doi:10.1038/nature19802 (2016).

9   Chen, J. S. *et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science* **360**, 436-439, doi:10.1126/science.aar6245 (2018).

10   Gootenberg, J. S. *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* **356**, 438-442, doi:10.1126/science.aam9321 (2017).

11   Gootenberg, J. S. *et al.* Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science* **360**, 439-444, doi:10.1126/science.aaq0179 (2018).

12   Harrington, L. B. *et al.* Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. *Science* **362**, 839-842, doi:10.1126/science.aav4294 (2018).

24

654   13   Teng, F. *et al.* CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar
655   sensitivity and single-base specificity. *Genome Biol* **20**, 132, doi:10.1186/s13059-019-
656   1742-z (2019).

657   14   Myhrvold, C. *et al.* Field-deployable viral diagnostics using CRISPR-Cas13. *Science*
658   **360**, 444-448, doi:10.1126/science.aas8836 (2018).

659   15   Broughton, J. P. *et al.* CRISPR-Cas12-based detection of SARS-CoV-2. *Nat*
660   *Biotechnol*, doi:10.1038/s41587-020-0513-4 (2020).

661   16   Ackerman, C. M. *et al.* Massively multiplexed nucleic acid detection using Cas13.
662   *Nature*, doi:10.1038/s41586-020-2279-8 (2020).

663   17   Guo, L. *et al.* SARS-CoV-2 detection with CRISPR diagnostics. *Cell Discov* **6**, 34,
664   doi:10.1038/s41421-020-0174-y (2020).

665   18   Joung, J. *et al.*, doi:10.1101/2020.05.04.20091231 (2020).

666   19   Hou, T. *et al.*, doi:10.1101/2020.02.22.20025460 (2020).

667   20   Lucia, C., Federico, P.-B. & Alejandra, G. C., doi:10.1101/2020.02.29.971127 (2020).

668   21   Ding, X., Yin, K., Li, Z. & Liu, C., doi:10.1101/2020.03.19.998724 (2020).

669   22   Azhar, M. *et al.*, doi:10.1101/2020.04.07.028167 (2020).

670   23   Rauch, J. N. *et al.*, doi:10.1101/2020.04.20.052159 (2020).

671   24   Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
672   contribution to global health. *Glob Chall* **1**, 33-46, doi:10.1002/gch2.1018 (2017).

673   25   Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data -
674   from vision to reality. *Euro Surveill* **22**, doi:10.2807/1560-7917.ES.2017.22.13.30494
675   (2017).

676   26   van Dorp, L. *et al.* Emergence of genomic diversity and recurrent mutations in SARS-
677   CoV-2. *Infect Genet Evol* **83**, 104351, doi:10.1016/j.meegid.2020.104351 (2020).

678   27   Wang, R., Hozumi, Y., Yin, C. & Wei, G.-W. Mutations on COVID-19 diagnostic
679   targets. *arXiv e-prints*, arXiv:2005.02188 (2020).
680   <https://ui.adsabs.harvard.edu/abs/2020arXiv200502188W>.

681   28   Di Giorgio, S., Martignano, F., Torcia, M. G., Mattiuz, G. & Conticello, S. G.
682   Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2.
683   *Science Advances*, doi:10.1126/sciadv.abb5813 (2020).

684   29   Kleinstiver, B. P. *et al.* Engineered CRISPR-Cas12a variants with increased activities
685   and improved targeting ranges for gene, epigenetic and base editing. *Nat Biotechnol*
686   **37**, 276-282, doi:10.1038/s41587-018-0011-0 (2019).

25

687 30 Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res*
688   **28**, E63, doi:10.1093/nar/28.12.e63 (2000).

689 31 Wu, A. *et al.* Genome Composition and Divergence of the Novel Coronavirus (2019-
690   nCoV) Originating in China. *Cell Host Microbe* **27**, 325-328,
691   doi:10.1016/j.chom.2020.02.001 (2020).

692 32 Piepenburg, O., Williams, C. H., Stemple, D. L. & Armes, N. A. DNA detection using
693   recombination proteins. *PLoS Biol* **4**, e204, doi:10.1371/journal.pbio.0040204 (2006).

694 33 Vincent, M., Xu, Y. & Kong, H. Helicase-dependent isothermal DNA amplification.
695   *EMBO Rep* **5**, 795-800, doi:10.1038/sj.embor.7400200 (2004).

696 34 Hajian, R. *et al.* Detection of unamplified target genes via CRISPR-Cas9 immobilized
697   on a graphene field-effect transistor. *Nat Biomed Eng* **3**, 427-437,
698   doi:10.1038/s41551-019-0371-x (2019).

699 35 Lu, R. *et al.* Development of a Novel Reverse Transcription Loop-Mediated
700   Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. *Virol Sin*,
701   doi:10.1007/s12250-020-00218-1 (2020).

702 36 Baek, Y. H. *et al.* Development of a reverse transcription-loop-mediated isothermal
703   amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg*
704   *Microbes Infect* **9**, 998-1007, doi:10.1080/22221751.2020.1756698 (2020).

705 37 Huang, W. E. *et al.* RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2.
706   *Microb Biotechnol*, doi:10.1111/1751-7915.13586 (2020).

707 38 Yan, C. *et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2)
708   by a reverse transcription loop-mediated isothermal amplification assay. *Clin*
709   *Microbiol Infect* **26**, 773-779, doi:10.1016/j.cmi.2020.04.001 (2020).

710 39 Sun, F. *et al.* Smartphone-based multiplex 30-minute nucleic acid test of live virus
711   from nasal swab extract. *Lab Chip* **20**, 1621-1627, doi:10.1039/d0lc00304b (2020).

712 40 Yu, L. *et al.* Rapid detection of COVID-19 coronavirus using a reverse transcriptional
713   loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. *Clin Chem*,
714   doi:10.1093/clinchem/hvaa102 (2020).

715 41 Park, G. S. *et al.* Development of Reverse Transcription Loop-Mediated Isothermal
716   Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2. *J*
717   *Mol Diagn*, doi:10.1016/j.jmoldx.2020.03.006 (2020).

718 42 Song, J., Bau, H. H. & El-Tholotha, M., doi:10.26434/chemrxiv.11860137.v1.

719 43 Bhadra, S., Riedel, T. E., Lakhotia, S., Tran, N. D. & Ellington, A. D.,
720   doi:10.1101/2020.04.13.039941 (2020).

26

721   44   Lalli, M. A. *et al.*, doi:10.1101/2020.05.07.20093542 (2020).

722   45   Lamb, L. E., Bartolone, S. N., Ward, E. & Chancellor, M. B.,
723   doi:10.1101/2020.02.19.20025155 (2020).

724   46   Zhang, Y. *et al.*, doi:10.1101/2020.02.26.20028373 (2020).

725   47   Ben-Assa, N. *et al.*, doi:10.1101/2020.04.22.20072389 (2020).

726   48   Dao Thi, V. L. *et al.*, doi:10.1101/2020.05.05.20092288 (2020).

727   49   Butler, D. J. *et al.*, doi:10.1101/2020.04.20.048066 (2020).

728   50   Kim, D. *et al.* The Architecture of SARS-CoV-2 Transcriptome. *Cell* **181**, 914-921
729   e910, doi:10.1016/j.cell.2020.04.011 (2020).

730

a

Sample Input → Isothermal Amplification → CRISPR-Cas Detection → Assay Readout

Purified RNA / Swab / Saliva | LAMP / RPA / HDA | Cas12 / Cas13 / Cas14 | Microplate Reader / Lateral flow / Chip

b

S2 PM

Copies per reaction:	2E6	2E5	2E4	2E3	2E2	2E1	2	NTC
Band intensity ratio:	2.33	2.41	2.87	2.65	2.85	0.22	0.21	0.21

S2 MM10

	2E6	2E5	2E4	2E3	2E2	2E1	2	NTC
	0.37	0.39	0.35	0.35	0.23	0.27	0.18	0.24

S1 PM + S2 PM

	2E6	2E5	2E4	2E3	2E2	2E1	2	NTC
Band intensity ratio:	1.33	1.67	1.76	1.33	2.02	0.25	0.26	0.24

S1 PM + S2 MM10

	2E6	2E5	2E4	2E3	2E2	2E1	2	NTC
	0.94	0.93	0.81	0.61	0.32	0.29	0.24	0.22

Test band / Control band